PROMISE-EPI study started in Zambia in December 2019.
The First Patient First Visit (FPFV) occurred on December 12th. The study was first initiated in 3 sites in Lusaka (Chilenje, Bauleni and Matero Main) and a new site (Chaisa) was opened in the capital in the end of March 2020. One year inclusion period is planned. More information on the study design are available on our web site and on clinicaltrials.gov
A feasibility investigation is ongoing in Burkina Faso to determine if PROMISE-EPI could be implemented there.